What Nublexa is?
Regorafenib is a multi-kinase inhibitor, indicated for the treatment of:
- Metastatic Colorectal Cancer
- Advanced Hepatocellular Carcinoma
- Also, Advanced Gastoinstenstial Stromal Tumors
What Regorafenib is?
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types.